Verde Announces Court Approval of Debt Renegotiation Agreement The Agreement Secures Extended Payment Terms and Reduced Interest Rates, Enhancing Liquidity SINGAPORE, April 15, 2025 (GLOBE NEWSWIRE) -- Verde Agritech Ltd (TSX: “NPK”) ("Verde” or the “Company”) is pleased to announce that the civil court has homologated Verde’s Debt Renegotiation Agreement, as disclosed in press releases dated October 2, 20241 and November 11, 20242. Terms Applicable to Adherent Creditors: The adherent creditors, representing 92.2% of the total outstanding debt, will be subject to the following conditio...
Verde Agritech Limited and Nautica Holdings Limited announce strategic transaction for high-grade magnetic rare earths exploration assets SINGAPORE, April 09, 2025 (GLOBE NEWSWIRE) -- Verde Agritech Ltd (TSX: “NPK”) (OTCQX: “VNPKF”) ("Verde” or the “Company”) and Nautica Holdings Limited (ACN 647 075 401), an Australian unlisted public company with AUD $1 million in cash available for investment, are pleased to jointly announce the execution of a Share Sale Agreement (“SSA”). Under the SSA, Nautica will acquire high-grade magnetic rare earths exploration assets located in Brazil ("Explora...
Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025 - Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical murine data strengthen case for specifically targeting pathologic forms of tau with the clinical-stage anti-tau antibody VY7523 - - Voyager to host live webcast on April 7 recapping key AD/PD™ 2025 data - LEXINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc...
Verde Announces Q4 and FY 2024 Results (All figures are in Canadian dollars, unless stated otherwise. Average exchange rate in FY 2024: C$1.00 = R$3.93) SINGAPORE, March 20, 2025 (GLOBE NEWSWIRE) -- Verde AgriTech Ltd (TSX: “NPK”) ("Verde” or the “Company”) announces its financial results for the full year ended December 31, 2024 (“FY 2024”) and the fourth quarter 2024 (“Q4 2024”), as audited by RSM SG Assurance LLP (“RSM”). "Looking back, 2023/24 will undoubtedly be remembered as one of the most challenging periods for Brazilian agriculture in this century. A historic number of farmers...
Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results - Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 - - Anti-tau antibody VY7523 was well tolerated in healthy volunteers and showed dose-proportional pharmacokinetics; initial tau PET imaging data in Alzheimer’s patients expected H2 2026 - LEXINGTON, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to...
Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast LEXINGTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2024 financial and operating results after market close on Tuesday, March 11, 2025. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET. A live webcast of the call will be available on the Investors section of the Voyager website at , and a replay of the call will be avai...
Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer’s Disease - Topline SAD data from healthy volunteers demonstrate safety, tolerability, and dose-proportional pharmacokinetics, supporting potentially best-in-class profile - - MAD study initiated in patients with early Alzheimer’s disease; initial tau PET imaging data expected in H2 2026 - LEXINGTON, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to ad...
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences LEXINGTON, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the Company will participate in multiple upcoming investor conferences: TD Cowen 45th Annual Health Care Conference, in Boston, including a fireside chat at 1:50 p.m. ET on March 3, 2025Stifel 2025 Virtual CNS Forum, including a fireside chat at 11:00 a.m. ET on March 19, 2025 Webcasts of the presentations will be available and ma...
Voyager Provides Update on SOD1 ALS Gene Therapy Program - Company to assess alternate payloads; no changes planned to novel capsid component - - Resulting shift of timeline and costs extends cash runway into mid-2027 – - All other programs remain on track; IND filings expected in 2025 for GBA1 and FA programs - LEXINGTON, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it has decided to assess alternate payloads related to its gene therapy program for su...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.